What is NDC 24201-150?

24201-150 is the product NDC for Medroxyprogesterone Acetate Injectable Suspension, Medroxyprogesterone acetate 150 mg/mL injection, suspension, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Medroxyprogesterone Acetate Injectable Suspension (Medroxyprogesterone acetate).

Hikma Pharmaceuticals USA Inc., NDC labeler code 24201. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Medroxyprogesterone Acetate Injectable Suspension?

None: this is the only finished product listed under this name.

NDC 24201-150

NDC codes

FDA NDC Directory

Product NDC (as listed)24201-150Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24201-0150Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
24201-150-01	2420101500124201015001	1 VIAL in 1 CARTON (24201-150-01) / 1 mL in 1 VIAL (24201-150-00)Marketed from May 1, 2023
24201-150-25	2420101502524201015025	25 VIAL in 1 CARTON (24201-150-25) / 1 mL in 1 VIAL (24201-150-00)Marketed from May 1, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Medroxyprogesterone Acetate Injectable Suspension
Generic name (nonproprietary): medroxyprogesterone acetate
Active ingredients: Medroxyprogesterone acetate — 150 mg/mL
Dosage form: Injection, Suspension
Route: Intramuscular
Labeler: Hikma Pharmaceuticals USA Inc.NDC labeler code 24201
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214309
Marketing start: May 1, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Progesterone Congeners (Chemical structure)
Identifiers: Product ID 24201-150_3bf1d302-025e-447c-8480-065dd9f01849SPL ID 3bf1d302-025e-447c-8480-065dd9f01849SPL set ID 0476eac5-d96c-4910-aa86-1ddeeefefe50RxCUI 1000126UNII C2QI4IOI2G
Pharmacologic class: Progestin

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J1050 — Injection, medroxyprogesterone acetate, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N424201015001 followed by a unit qualifier and the quantity

Package 24201-0150-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 8, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. Medroxyprogesterone acetate injectable suspension is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use: The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are consider…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 24201-150

What is NDC 24201-150?: 24201-150 is the product NDC for Medroxyprogesterone Acetate Injectable Suspension, Medroxyprogesterone acetate 150 mg/mL injection, suspension, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Medroxyprogesterone Acetate Injectable Suspension (Medroxyprogesterone acetate).
What is the active ingredient?: Medroxyprogesterone acetate.
Who is the labeler?: Hikma Pharmaceuticals USA Inc., NDC labeler code 24201. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Medroxyprogesterone Acetate Injectable Suspension?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Yes: J1050, Injection, medroxyprogesterone acetate, 1 mg. See Billing references above.

Medroxyprogesterone Acetate Injectable Suspension (Medroxyprogesterone acetate) NDC 24201-150